Theravance Biopharma, Inc. (TBPH)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Rick E. Winningham M.B.A. | CEO & Director | 1.55M | -- | 1960 |
| Mr. Aziz Sawaf C.F.A. | Senior VP & CFO | 660.15k | -- | 1982 |
| Mr. Brett A. Grimaud Esq. | Senior VP, General Counsel & Secretary | 690.87k | -- | 1974 |
| Mr. Stuart Knight | Senior VP of IT&I and Chief Information Officer | -- | -- | -- |
| Ms. Rhonda F. Farnum | Chief Business Officer and Senior VP of Commercial & Medical Affairs | 942.81k | -- | 1965 |
| Ms. Stacy L. Pryce | Senior VP & Chief Strategy Officer | -- | -- | -- |
| Dr. Aine Miller Ph.D. | Senior VP of Development & Head of Ireland Office | -- | -- | 1977 |
Theravance Biopharma, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 97
Description
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Corporate Governance
Upcoming Events
August 4, 2025 at 8:00 PM UTC - August 8, 2025 at 8:00 PM UTC
Theravance Biopharma, Inc. Earnings Date